AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
estetrol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| estrogens | 5450 | 15183-37-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Estetrol is a synthetic analogue of a native estrogen present during pregnancy, that is selective for nuclear estrogen receptors ERalpha and ERbeta. It is used in combination with drospirenone, a spironolactone analogue with anti-mineralocorticoid and antiandrogenic activity, (nextstellis) as oral contraceptive.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.884 | Moderate | 0.66 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.393 | Moderate | 0.66 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 26.182 | 10^-6 cm/s | Moderate | 0.66 |
| dh-clint | Dog hepatocyte intrinsic clearance | 6.637 | uL/min/10^6 cells | Moderate | 0.66 |
| dppb | Dog plasma protein binding (% unbound) | 19.780 | % | Moderate | 0.66 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 36.740 | % | Moderate | 0.66 |
| herg | hERG pIC50 | 4.541 | pIC50 | Moderate | 0.66 |
| hh-clint | Human hepatocyte intrinsic clearance | 3.690 | uL/min/10^6 cells | Moderate | 0.66 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.214 | uL/min/mg protein | Moderate | 0.66 |
| hppb | Human plasma protein binding (% unbound) | 20.300 | % | Moderate | 0.66 |
| kinase-safety-class | ACVR2B,BRAF,BTK,CAMK2D,CDK5,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1,ZAP70 | 22 | |||
| kinase-selectivity-class | EIF2AK3,GRK2,MAP2K6 | 3 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 5.383 | Moderate | 0.66 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 46.132 | Moderate | 0.66 | |
| mppb | Mouse plasma protein binding (% unbound) | 20.490 | Moderate | 0.66 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 11.858 | Moderate | 0.66 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 27.870 | % | Moderate | 0.66 |
| rh-clint | Rat hepatocyte intrinsic clearance | 35.563 | uL/min/10^6 cells | Moderate | 0.66 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 71.670 | % | Moderate | 0.66 |
| rppb | Rat plasma protein binding (% unbound) | 16.790 | % | Moderate | 0.66 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 564.937 | uM | Moderate | 0.66 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 15, 2021 | FDA | MAYNE PHARMA | |
| May 19, 2021 | EMA | Gedeon Richter Plc; Estetra SPRL |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G03AA18 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
| ATC | G03CA10 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Natural and semisynthetic estrogens, plain |
| MeSH PA | D003270 | Contraceptive Agents |
| MeSH PA | D012102 | Reproductive Control Agents |
| FDA CS | M0447348 | Estradiol Congeners |
| FDA MoA | N0000000100 | Estrogen Receptor Agonists |
| FDA EPC | N0000175825 | Estrogen |
| CHEBI has role | CHEBI:49323 | contraceptive drug |
| CHEBI has role | CHEBI:49325 | oral contraceptive |
| CHEBI has role | CHEBI:50114 | estrogen |
| CHEBI has role | CHEBI:63951 | estrogen receptor agonist |
| CHEBI has role | CHEBI:76967 | human xenobiotic metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
Related Drugs by ATC class:
G03AA Progestogens and estrogens, fixed combinations 17 drugs
G03CA Natural and semisynthetic estrogens, plain 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Prevent pregnancy | indication | 5935008 | |
| Hepatocellular carcinoma | contraindication | 25370001 | |
| Acute hepatitis | contraindication | 37871000 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Atrial fibrillation | contraindication | 49436004 | DOID:0060224 |
| Coronary arteriosclerosis | contraindication | 53741008 | DOID:3393 |
| Cerebrovascular disease | contraindication | 62914000 | DOID:6713 |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hepatocellular adenoma | contraindication | 78058005 | |
| Renal impairment | contraindication | 236423003 | |
| Carcinoma of breast | contraindication | 254838004 | DOID:3459 |
| Adrenal insufficiency | contraindication | 386584007 | DOID:10493 |
| Venous thromboembolic disease | contraindication | 429098002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 3MG;14.2MG | NEXTSTELLIS | MAYNE PHARMA | N214154 | April 15, 2021 | RX | TABLET | ORAL | 7732430 | Jan. 15, 2028 | USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY |
| 3MG;14.2MG | NEXTSTELLIS | MAYNE PHARMA | N214154 | April 15, 2021 | RX | TABLET | ORAL | 12427114 | June 17, 2036 | USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY |
| 3MG;14.2MG | NEXTSTELLIS | MAYNE PHARMA | N214154 | April 15, 2021 | RX | TABLET | ORAL | 12233074 | Feb. 9, 2043 | USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY |
| 3MG;14.2MG | NEXTSTELLIS | MAYNE PHARMA | N214154 | April 15, 2021 | RX | TABLET | ORAL | 12458649 | Oct. 1, 2043 | USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 3MG;14.2MG | NEXTSTELLIS | MAYNE PHARMA | N214154 | April 15, 2021 | RX | TABLET | ORAL | April 15, 2026 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Estrogen receptor | Nuclear hormone receptor | MODULATOR | Ki | 8.31 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Estrogen receptor beta | Nuclear hormone receptor | MODULATOR | Ki | 7.72 | SCIENTIFIC LITERATURE | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| D11513 | KEGG_DRUG |
| 2055649-81-3 | SECONDARY_CAS_RN |
| C0014899 | UMLSCUI |
| CHEBI:142773 | CHEBI |
| 4OH | PDB_CHEM_ID |
| CHEMBL6068423 | ChEMBL_ID |
| 27125 | PUBCHEM_CID |
| DB12235 | DRUGBANK_ID |
| CHEMBL1230314 | ChEMBL_ID |
| D004953 | MESH_DESCRIPTOR_UI |
| C000718213 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11591 | IUPHAR_LIGAND_ID |
| 1179488005 | SNOMEDCT_US |
| 1179489002 | SNOMEDCT_US |
| 1269193003 | SNOMEDCT_US |
| 4040424 | VANDF |
| 10439 | INN_ID |
| 39469 | MMSL |
| d09730 | MMSL |
| 018700 | NDDF |
| ENB39R14VF | UNII |
| 2539031 | RXNORM |
| ENB39R14VF | INXIGHT DRUGS |
Pharmaceutical products:
None